
Gregory Gerdeman- Ph.D. Pharmacology
- Director of Education & Research at SPECCX
Gregory Gerdeman
- Ph.D. Pharmacology
- Director of Education & Research at SPECCX
About
11
Publications
5,853
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
2,531
Citations
Introduction
Current institution
SPECCX
Current position
- Director of Education & Research
Additional affiliations
January 2004 - present
January 2003 - December 2008
January 2001 - December 2002
Education
August 1995 - September 2001
August 1991 - May 1995
Centre College
Field of study
- Biochemistry and Molecular Biology
Publications
Publications (11)
Endocannabinoids (eCB) are endogenous ligands for cannabinoid receptors that are densely expressed in brain networks responsible for reward. Recent work shows that exercise activates the eCB system in humans and other mammals, suggesting eCBs are partly responsible for the reported improvements in mood and affect following aerobic exercise in human...
Humans report a wide range of neurobiological rewards following moderate and intense aerobic activity, popularly referred to as the 'runner's high', which may function to encourage habitual aerobic exercise. Endocannabinoids (eCBs) are endogenous neurotransmitters that appear to play a major role in generating these rewards by activating cannabinoi...
Exercise is a naturally rewarding behaviour in human beings and can be associated with feelings of euphoria and analgesia. The endocannabinoid system may play a role in the perception of neurobiological rewards during and after prolonged exercise. Mice from lines that have been selectively bred for high voluntary wheel running (high runner or HR li...
The CB(1) cannabinoid receptor is implicated in the rewarding properties of many drugs of abuse, including cocaine. While CB(1) receptor involvement in the acute rewarding properties of cocaine is controversial, CB(1) antagonists such as SR141716 (rimonabant) have clearly been found to prevent cue- and cocaine-elicited reinstatement of cocaine self...
Multiple lines of evidence indicate a prominent role for the cannabinoid signaling system in the control of basal ganglia
function, exerted by modulating the activity of various classic neurotransmitters, such as GABA, dopamine, or glutamate, that
operate within this circuit. Throughout the basal ganglia, the activity-evoked release of endocannabin...
In the study of synaptic transmission, the field of endocannabinoid research is flowering. A wealth of recent findings has
revealed critical molecular underpinnings of endocannabinoid generation and signal transduction, and the subcellular localization
of these processes within neurons has been mapped with increasing detail. Sophisticated technique...
Activation of the CB1 cannabinoid receptor inhibits neurotransmission at numerous synapses in the brain. Indeed, CB1 is essential for certain types of both short- and long-term synaptic depression. It was demonstrated recently that CB1 is critical for activity-dependent long-term depression (LTD) at glutamatergic corticostriatal synapses in acute b...
British Journal of Pharmacology (2003) 140, 781–789. doi:10.1038/sj.bjp.0705466
Drug addiction can take control of the brain and behavior, activating behavioral patterns that are directed excessively and compulsively toward drug usage. Such patterns often involve the development of repetitive and nearly automatic behaviors that we call habits. The striatum, a subcortical brain region important for proper motor function as well...
The striatum functions critically in movement control and habit formation. The development and function of cortical input to the striatum are thought to be regulated by activity-dependent plasticity of corticostriatal glutamatergic synapses. Here we show that the induction of a form of striatal synaptic plasticity, long-term depression (LTD), is de...
CB1 cannabinoid receptors in the neostriatum mediate profound motor deficits induced when cannabinoid drugs are administered to rodents. Because the CB1 receptor has been shown to inhibit neurotransmitter release in various brain areas, we investigated the effects of CB1 activation on glutamatergic synaptic transmission in the dorsolateral striatum...